CO6150167A2 - Analogos de 2-fenoxipirimidinona - Google Patents

Analogos de 2-fenoxipirimidinona

Info

Publication number
CO6150167A2
CO6150167A2 CO09028167A CO09028167A CO6150167A2 CO 6150167 A2 CO6150167 A2 CO 6150167A2 CO 09028167 A CO09028167 A CO 09028167A CO 09028167 A CO09028167 A CO 09028167A CO 6150167 A2 CO6150167 A2 CO 6150167A2
Authority
CO
Colombia
Prior art keywords
alkyl
amino
mono
independently selected
cycloalkyl
Prior art date
Application number
CO09028167A
Other languages
English (en)
Inventor
Rajagopal Bakthavatchalam
Scott Michael Capitosti
Jianjun Xu
Bertrand L Chenard
Manuka Ghosh
Charles A Blum
Original Assignee
Neurogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurogen Corp filed Critical Neurogen Corp
Publication of CO6150167A2 publication Critical patent/CO6150167A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • AIDS & HIV (AREA)
  • Child & Adolescent Psychology (AREA)
  • Communicable Diseases (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

1.- Un compuesto de la fórmula: o una sal farmacéuticamente aceptable o hidrato del mismo, en donderepresenta un heteroarilo de 5 ó 6 miembros fusionado que contiene 1, 2 ó 3 heteroátomos independientemente escogidos de O, N y S, con los átomos de anillo restantes siendo carbono, en donde el heteroarilo fusionado es sustituido con de 0 a 3 sustituyentes independientemente escogidos de amino, hidroxi, alquilo de C1-C6, hidroxialquilo de C1-C6, (cicloalquilo de C3-C7)alquilo de C0-C2, halogenoalquilo de C1-C6, alcoxi de C1-C6, éter alquílico de C2-C6, alcanoiloxi de C1-C6, alquilsulfonilamino de C1-C6, alcanoilamino de C1-C6, y mono- o di-(alquilo de C1-C6)amino; Ar es fenilo o un heteroarilo de 5 ó 6 miembros, cada uno de los cuales es sustituido con de 0 a 4 sustituyentes que son independientemente escogidos de halógeno, ciano, amino, nitro, alquilo de C1-C6, alquenilo de C2-C6, alquinilo de C2-C6, halogenoalquilo de C1-C6, hidroxialquilo de C1-C6, alcoxi de C1-C6, halogenoalcoxi de C1-C6, (cicloalquilo de C3-C7)alquilo de C0-C4, y mono- o di- (alquilo de C1-C6)amino; y R3 representa de 0 a 4 sustituyentes que son independientemente escogidos de halógeno, hidroxi, ciano, amino, nitro, alquilo de C1-C6, alquenilo de C2-C6, alquinilo de C2-C6, halogenoalquilo de C1-C6, hidroxialquilo de C1-C6, alcoxi de C1-C6, halogenoalcoxi de C1-C6, (cicloalquilo de C3-C7)alquilo de C0-C4, mono- o di-(alquilo de C1-C6)amino, y mono- o di-(alquilo de C1-C6)aminosulfonilo.
CO09028167A 2006-08-23 2009-03-18 Analogos de 2-fenoxipirimidinona CO6150167A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82325806P 2006-08-23 2006-08-23

Publications (1)

Publication Number Publication Date
CO6150167A2 true CO6150167A2 (es) 2010-04-20

Family

ID=39107411

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09028167A CO6150167A2 (es) 2006-08-23 2009-03-18 Analogos de 2-fenoxipirimidinona

Country Status (22)

Country Link
US (2) US8003656B2 (es)
EP (1) EP2061794B1 (es)
JP (1) JP5421108B2 (es)
KR (1) KR20090043583A (es)
CN (2) CN101506210A (es)
AU (1) AU2007288203B2 (es)
BR (1) BRPI0716582A2 (es)
CA (1) CA2660957C (es)
CO (1) CO6150167A2 (es)
CR (1) CR10675A (es)
EA (1) EA200900330A1 (es)
ES (1) ES2399928T3 (es)
GT (1) GT200900040A (es)
IL (1) IL197043A0 (es)
MA (1) MA30720B1 (es)
MX (1) MX2009002066A (es)
NI (1) NI200900023A (es)
NO (1) NO20091182L (es)
SV (1) SV2009003173A (es)
TW (1) TW200825089A (es)
WO (1) WO2008024438A2 (es)
ZA (1) ZA200901163B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0509573D0 (en) * 2005-05-11 2005-06-15 Merck Sharp & Dohme Therapeutic compounds
ES2399928T3 (es) 2006-08-23 2013-04-04 Neurogen Corporation Análogos de 2-fenoxipirimidinona
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
SG11201601616SA (en) 2013-09-09 2016-04-28 Peloton Therapeutics Inc Aryl ethers and uses thereof
EP3180340B1 (en) * 2014-08-11 2018-10-10 Hydra Biosciences, Inc. Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives
US10155726B2 (en) 2015-03-11 2018-12-18 Peloton Therapeutics, Inc. Substituted pyridines and uses thereof
US10278942B2 (en) 2015-03-11 2019-05-07 Peloton Therapeutics, Inc. Compositions for use in treating pulmonary arterial hypertension
WO2016144825A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Aromatic compounds and uses thereof
WO2016145045A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Compositions for use in treating glioblastoma
US10335388B2 (en) 2015-04-17 2019-07-02 Peloton Therapeutics, Inc. Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof
WO2020146449A1 (en) * 2019-01-08 2020-07-16 Texas Tech University System Small molecule analogs of the protein e4orf1 in the treatment and prevention of metabolic disorders

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0364598A4 (en) * 1988-03-02 1992-01-15 Yoshitomi Pharmaceutical Industries, Ltd. 3,4-dihydrothieno 2,3-d¨pyrimidine compounds and pharmaceutical application thereof
US5202328A (en) * 1991-03-06 1993-04-13 Merck & Co., Inc. Substituted fused pyrimidinones
ATE227293T1 (de) * 1996-05-15 2002-11-15 Pfizer 2,3-disubstituierte-(5,6)-heteroarylkondensiert - pyrimidin-4-one
IL132474A (en) 1997-05-08 2003-05-29 Agrevo Uk Ltd 3,4-dihydrothienopyrimidine-4-(thi) ones for combating plant fungi and a novel such compound
US6627755B1 (en) * 1997-06-09 2003-09-30 Pfizer Inc Quinazolin-4-one AMPA antagonists
IL125950A0 (en) * 1997-09-05 1999-04-11 Pfizer Prod Inc Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
US6323208B1 (en) * 1997-09-05 2001-11-27 Pfizer Inc Atropisomers of 2,3-disubstituted-(5.6)-heteroaryl fused-pyrimidin-4-ones
WO2002026718A2 (en) 2000-09-29 2002-04-04 Millennium Pharmaceutical, Inc. Bicyclic pyrimidin-4-one based inhibitors of factor xa
JP2004518732A (ja) * 2001-02-14 2004-06-24 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー マトリックスメタロプロテイナーゼ阻害剤としてのチエノ’２，３−ｄピリミジンジオン誘導体
CN1500089A (zh) 2001-03-26 2004-05-26 ��˹��ŵ�� 作为辣椒素受体拮抗剂用于治疗疼痛的稠合吡啶衍生物
EP1430161B1 (de) * 2001-09-28 2005-06-15 DaimlerChrysler AG Hochfester duplex-/triplex-leichtbaustahl und seine verwendung
EP1461311A2 (en) 2001-12-26 2004-09-29 Bayer HealthCare AG Urea derivatives as vr1-antagonists
US6984647B2 (en) 2002-05-17 2006-01-10 Janssen Pharmaceutica N.V. Aminotetralin-derived urea modulators of vanilloid VR1 receptor
WO2003106435A1 (en) 2002-06-18 2003-12-24 Sankyo Company, Limited Fused-ring pyrimidin-4(3h)-one derivatives, processes for the preparation and uses thereof
AU2003273856A1 (en) 2002-09-24 2004-04-19 Bayer Healthcare Ag Vr1 antagonists for the treatment of urological disorders
GB0223730D0 (en) 2002-10-11 2002-11-20 Novartis Ag Organic compounds
US20040132732A1 (en) * 2002-10-21 2004-07-08 Wei Han Quinazolinones and derivatives thereof as factor Xa inhibitors
US20040242568A1 (en) * 2003-03-25 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
GB0326633D0 (en) 2003-11-14 2003-12-17 Merck Sharp & Dohme Therapeutic agents
EP1687306A1 (en) * 2003-11-14 2006-08-09 MERCK SHARP & DOHME LTD. Bicyclic pyrimidin-4-(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1 receptor (vr1)
US7544803B2 (en) * 2004-01-23 2009-06-09 Amgen Inc. Vanilloid receptor ligands and their use in treatments
GB0412769D0 (en) 2004-06-08 2004-07-07 Novartis Ag Organic compounds
AR051596A1 (es) 2004-10-26 2007-01-24 Irm Llc Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios
JP2009536608A (ja) * 2005-05-11 2009-10-15 メルク シャープ エンド ドーム リミテッド バニロイド−１受容体（ｖｒ１）の機能を調節する２，３−置換縮合二環式ピリミジン４−（３ｈ）−オン
GB0509573D0 (en) 2005-05-11 2005-06-15 Merck Sharp & Dohme Therapeutic compounds
CN1318429C (zh) * 2005-07-25 2007-05-30 华中师范大学 具有杀菌活性的取代噻吩并[3',2':5,6]吡啶并[4,3－d]嘧啶－4(3H)－酮及制备
US7893260B2 (en) 2005-11-04 2011-02-22 Hydra Biosciences, Inc. Substituted quinazolin-4-one compounds for antagonizing TRPV3 function
CN101563349A (zh) * 2006-08-23 2009-10-21 神经能质公司 经卤烷基取代的嘧啶酮衍生物
ES2399928T3 (es) 2006-08-23 2013-04-04 Neurogen Corporation Análogos de 2-fenoxipirimidinona
CA2668579A1 (en) * 2006-11-06 2008-06-05 Neurogen Corporation Cis-cyclohexyl substituted pyrimidinone derivatives
WO2008156607A1 (en) 2007-06-12 2008-12-24 Neurogen Corporation Substituted pyrimidinones
WO2009100403A1 (en) 2008-02-07 2009-08-13 Neurogen Corporation Substituted aryl pyrimidinones
WO2009121036A2 (en) 2008-03-27 2009-10-01 Neurogen Corporation Substituted aryl pyrimidinone derivatives

Also Published As

Publication number Publication date
EP2061794B1 (en) 2012-12-05
EA200900330A1 (ru) 2009-08-28
US20120208829A1 (en) 2012-08-16
EP2061794A2 (en) 2009-05-27
TW200825089A (en) 2008-06-16
EP2061794A4 (en) 2010-09-08
IL197043A0 (en) 2009-11-18
CR10675A (es) 2009-04-17
CN101506210A (zh) 2009-08-12
MA30720B1 (fr) 2009-09-01
KR20090043583A (ko) 2009-05-06
ZA200901163B (en) 2010-08-25
AU2007288203A1 (en) 2008-02-28
WO2008024438A2 (en) 2008-02-28
WO2008024438A3 (en) 2008-11-27
BRPI0716582A2 (pt) 2013-10-08
MX2009002066A (es) 2009-03-06
CN104292229A (zh) 2015-01-21
CA2660957A1 (en) 2008-02-28
JP2010502576A (ja) 2010-01-28
ES2399928T3 (es) 2013-04-04
GT200900040A (es) 2010-03-16
JP5421108B2 (ja) 2014-02-19
CA2660957C (en) 2016-10-11
US8003656B2 (en) 2011-08-23
NI200900023A (es) 2010-03-05
US8759361B2 (en) 2014-06-24
NO20091182L (no) 2009-05-14
AU2007288203B2 (en) 2013-01-17
US20090069347A1 (en) 2009-03-12
SV2009003173A (es) 2010-08-10

Similar Documents

Publication Publication Date Title
CO6150167A2 (es) Analogos de 2-fenoxipirimidinona
CO6190582A2 (es) Derivados de heteroarilamida
PE20190329A1 (es) Compuestos moduladores de fxr (nr1h4)
NI201100181A (es) Análogos de isoxazol - 3 (2h ) -ona como agentes terapéuticos
AR085327A1 (es) Inhibidores del virus de la hepatitis c
AR089143A1 (es) Triazolopiridinas sustituidas con actividad inhibidora de ttk
RU2018121834A (ru) Новое соединение бифенила или его соль
AR048289A1 (es) Eteres de anillos imidazo sulfona sustituidos.
CO6241157A2 (es) "derivados de 6-(pirrolidin-3-il)-1h-pirazolo{3,4-d}pirimidin-4(5h)-ona utiles como inhibidores de pde9"
CO6321230A2 (es) Compuesto espiro, una sal aceptable para uso farmaceutico y un solvato del mismo y composicion farmaceutica que lo contenga
CO6210729A2 (es) Derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona procedimientos para su preparacion y su uso como agente farmaceutico
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
CO6251318A2 (es) Compuestos heterociclicos de 5 miembros como antagonistas p2x7
AR068846A1 (es) Compuestos derivados de pirrolo (2,3d)-pirimidina inhibidores de la actividad de pkb, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos como agentes anticancer
AR062679A1 (es) Derivados de eter diarilico y usos de los mismos
AR057855A1 (es) Derivados de pirazina y composicion farmaceutica
AR079486A1 (es) Compuestos heterociclicos nitrogenados de oxima, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades proliferativas.
ECSP088479A (es) Derivados de oxadiazol
AR098666A1 (es) Compuestos de biarilacetamida y sus métodos de uso
ES2637167T3 (es) Compuestos de tetrahidro-pirido-piridina y tetrahidro-pirido-pirimidina y su uso como moduladores de los receptores de C5a
AR080467A1 (es) Derivados tetrazolicos moduladores selectivos de receptores cb2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del dolor y otras enfermedades
CO6251294A2 (es) Derivados de 9-(pirazol-3-il)-9h-purin-2-amina y 3-(pirazol-3-il)-3h-imidazol4,5-b piridin-5-amina y su uso para el tratamiento del cancer
CO2021003115A2 (es) Inhibidores de sarcómeros cardíacos
AR067058A1 (es) Oxazolidinonas sustituidas y su uso para preparar medicamentos
AR094762A1 (es) Compuestos de hexahidropirano[3,4-d][1,3]tiazin-2-amina sustituida con heteroarilo